Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
2.
Certain surgical gestures during prostate removal linked to better sexual function recovery
3.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
4.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
5.
ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?
1.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
2.
Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care
3.
Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management
4.
Understanding Protein C Deficiency: Symptoms, Causes, and Treatment
5.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Thromboprophylaxis In Medical Settings- An Update
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation